Upregulation of CBP by PLY can cause permeability of blood‐brain barrier to increase meningitis

Chen, Jia-Quan; Li, Nannan; Wang, Bowen; Liu, Xiufang; Liu, Jialin; Chang, Qing

doi:10.1002/jbt.22333

Cited by 9 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pneumolysin, a cytolysin and Toll Like Receptor 4 agonist is implicated in directly toxic effects on host cells, particularly within the BBB and hippocampus [86,87]. Others stimulate CERB binding protein (CBP) and receptor for advanced glycation end products (RAGE), increasing Tumour Necrosis Factor alpha (TNF-α) levels and promoting BBB disruption [88,89 ▪ ].…”

Section: Pathogenesismentioning

confidence: 99%

Acute bacterial meningitis

Wall

Chan

Gil

et al. 2021

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of review Community-acquired bacterial meningitis is a continually changing disease. This review summarises both dynamic epidemiology and emerging data on pathogenesis. Updated clinical guidelines are discussed, new agents undergoing clinical trials intended to reduce secondary brain damage are presented. Recent findings Conjugate vaccines are effective against serotype/serogroup-specific meningitis but vaccine escape variants are rising in prevalence. Meningitis occurs when bacteria evade mucosal and circulating immune responses and invade the brain: directly, or across the blood–brain barrier. Tissue damage is caused when host genetic susceptibility is exploited by bacterial virulence. The classical clinical triad of fever, neck stiffness and headache has poor diagnostic sensitivity, all guidelines reflect the necessity for a low index of suspicion and early Lumbar puncture. Unnecessary cranial imaging causes diagnostic delays. cerebrospinal fluid (CSF) culture and PCR are diagnostic, direct next-generation sequencing of CSF may revolutionise diagnostics. Administration of early antibiotics is essential to improve survival. Dexamethasone partially mitigates central nervous system inflammation in high-income settings. New agents in clinical trials include C5 inhibitors and daptomycin, data are expected in 2025. Summary Clinicians must remain vigilant for bacterial meningitis. Constantly changing epidemiology and emerging pathogenesis data are increasing the understanding of meningitis. Prospects for better treatments are forthcoming.

show abstract

Section: Pathogenesismentioning

confidence: 99%

Acute bacterial meningitis

Wall

Chan

Gil

et al. 2021

Current Opinion in Neurology

View full text Add to dashboard Cite

show abstract

“…PLY (pneumolysin), a cytotoxin from pneumococcus, is related to the infection across BBB. PLY leads to the high expression of CERB-binding protein (CBP), which can lead to releasing of tumor necrosis factor α thereby enhancing apoptosis of cells, a signi icant factor leading to permeabilization of BBB [127].…”

Section: Miscellanous Disordersmentioning

confidence: 99%

Central nervous system diseases associated with blood brain barrier breakdown - A Comprehensive update of existing literatures

Dutta¹

2020

J Neurosci Neurol Disord

View full text Add to dashboard Cite

Blood vessels that supply and feed the central nervous system (CNS) possess unique and exclusive properties, named as blood–brain barrier (BBB). It is responsible for tight regulation of the movement of ions, molecules, and cells between the blood and the brain thereby maintaining controlled chemical composition of the neuronal milieu required for appropriate functioning. It also protects the neural tissue from toxic plasma components, blood cells and pathogens from entering the brain. In this review the importance of BBB and its disruption causing brain pathology and progression to different neurological diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD) etc. will be discussed.

show abstract

“…Pneumolysin has recently been demonstrated to induce the expression of CERB-binding protein (CBP), a coactivator of transcription. This results in the release of TNF-α and IL-6, which in turn lead to increased permeability of the BBB through increased apoptosis of the cells both in vivo and in vitro [101]. It has furthermore been implicated in paracellular traversal of the BBB by S. pneumoniae as a result of reduced barrier integrity [102].…”

Section: Roles Of Bacterial Virulence Factors During Invasion Thromentioning

confidence: 99%

Virulence Factors of Meningitis-Causing Bacteria: Enabling Brain Entry across the Blood–Brain Barrier

Herold

Schroten

Schwerk

2019

IJMS

View full text Add to dashboard Cite

Infections of the central nervous system (CNS) are still a major cause of morbidity and mortality worldwide. Traversal of the barriers protecting the brain by pathogens is a prerequisite for the development of meningitis. Bacteria have developed a variety of different strategies to cross these barriers and reach the CNS. To this end, they use a variety of different virulence factors that enable them to attach to and traverse these barriers. These virulence factors mediate adhesion to and invasion into host cells, intracellular survival, induction of host cell signaling and inflammatory response, and affect barrier function. While some of these mechanisms differ, others are shared by multiple pathogens. Further understanding of these processes, with special emphasis on the difference between the blood–brain barrier and the blood–cerebrospinal fluid barrier, as well as virulence factors used by the pathogens, is still needed.

show abstract

Upregulation of CBP by PLY can cause permeability of blood‐brain barrier to increase meningitis

Cited by 9 publications

References 22 publications

Acute bacterial meningitis

Acute bacterial meningitis

Central nervous system diseases associated with blood brain barrier breakdown - A Comprehensive update of existing literatures

Virulence Factors of Meningitis-Causing Bacteria: Enabling Brain Entry across the Blood–Brain Barrier

Contact Info

Product

Resources

About